Market capitalization | $391.87m |
Enterprise Value | $342.45m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.52 |
P/S ratio (TTM) P/S ratio | 6.32 |
P/B ratio (TTM) P/B ratio | 2.02 |
Revenue growth (TTM) Revenue growth | 20.97% |
Revenue (TTM) Revenue | $62.02m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
5 Analysts have issued a Theravance Biopharma Inc forecast:
5 Analysts have issued a Theravance Biopharma Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 62 62 |
21%
21%
|
|
Gross Profit | 56 56 |
23%
23%
|
|
EBITDA | -33 -33 |
48%
48%
|
EBIT (Operating Income) EBIT | -39 -39 |
44%
44%
|
Net Profit | -46 -46 |
83%
83%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of organ-selective medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
Head office | Cayman Islands |
CEO | Rick Winningham |
Employees | 99 |
Founded | 2013 |
Website | www.theravance.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.